Cargando…
Tirzepatide and prevention of chronic kidney disease
Tirzepatide is a twincretin recently approved to improve glycemic control in type 2 diabetes mellitus (T2DM). More specifically, tirzepatide is an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP1) receptors. In recent clinical trials in per...
Autores principales: | Bosch, Catalina, Carriazo, Sol, Soler, María José, Ortiz, Alberto, Fernandez-Fernandez, Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157759/ https://www.ncbi.nlm.nih.gov/pubmed/37151412 http://dx.doi.org/10.1093/ckj/sfac274 |
Ejemplares similares
-
Coronavirus disease 2019 in chronic kidney disease
por: D’Marco, Luis, et al.
Publicado: (2020) -
Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease
por: Donate-Correa, Javier, et al.
Publicado: (2022) -
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023) -
Genetic kidney diseases as an underrecognized cause of chronic kidney disease: the key role of international registry reports
por: Torra, Roser, et al.
Publicado: (2021) -
The new Clinical Kidney Journal, 4 years later
por: Ortiz, Alberto, et al.
Publicado: (2019)